• This record comes from PubMed

Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs

. 2017 Dec 04 ; 56 (49) : 15545-15549. [epub] 20171109

Language English Country Germany Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Cancer cells produce elevated levels of reactive oxygen species, which has been used to design cancer specific prodrugs. Their activation relies on at least a bimolecular process, in which a prodrug reacts with ROS. However, at low micromolar concentrations of the prodrugs and ROS, the activation is usually inefficient. Herein, we propose and validate a potentially general approach for solving this intrinsic problem of ROS-dependent prodrugs. In particular, known prodrug 4-(N-ferrocenyl-N-benzylaminocarbonyloxymethyl)phenylboronic acid pinacol ester was converted into its lysosome-specific analogue. Since lysosomes contain a higher concentration of active ROS than the cytoplasm, activation of the prodrug was facilitated with respect to the parent compound. Moreover, it was found to exhibit high anticancer activity in a variety of cancer cell lines (IC50 =3.5-7.2 μm) and in vivo (40 mg kg-1 , NK/Ly murine model) but remained weakly toxic towards non-malignant cells (IC50 =15-30 μm).

References provided by Crossref.org

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...